Fig. 6: Bispecific antibody labeling of exosomes was used as synthetic organelles that bridge the T cell and CD38+ myeloma cell.
From: Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
A Construction process and action mode of bispecific antibodies modified exosomes (aCD3-aCD38-EXOs); B Compared with aCD38-EXOs, aCD3-aCD38-EXOs mediated the binding of T cells and MM cells to each other.
